Asset profile
NA-931
Small molecule
Evidence outlook · lead readout
NCT06564753 · Weight Loss, Obesity, Body Weight, Body Weight Changes
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06564753: The study randomized 126 participants to four NA-931 dose groups or placebo and used triple blinding of participants, care providers, and investigators. Its primary endpoint was the clinical measure of percentage change in body weight at Week 13, but results and statistical comparisons are not available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
August 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.